Structure (Sirolimus Oral Solution 1)
Sirolimus Solution
Product Images NDC 66689-347
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Sirolimus (NDC 66689-347). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Vistapharm, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Container Label (Sirolimus Oral Solution 10)
This is an oral solution of Sirolimus packaged in a 60mL container with NDC code 66689-347-02. Each milliliter of the solution contains 1mg of Sirolimus along with additional compounds such as ethanol, fosphaldyiholne, and polysorbate 80. The usual dosage information is available in the package insert. The solution must be refrigerated and protected from light. It has to be consumed within a month of opening the container. This product is for oral use only and must be kept out of reach of children. The manufacturer is Novitium Pharma LLC and the product is distributed by VistaPharm, Inc.*
Carton-label (Sirolimus Oral Solution 11)
This is a medication description for Sirolimus Oral Solution manufactured by "Rovtum Pramaiic". The recommended usage and storage information of the medication is provided. It is advised to use the contents within 1 month after opening the package and keep it away from children's reach. The medication is for oral use only and should be protected from light. The manufacturer's contact information is also mentioned.*
Patient-kit (Sirolimus Oral Solution 12)
Sirolimus Oral Solution is a medication indicated to prevent rejection of kidney transplants in adults. The package insert contains instructions for use. Each mL contains 1.0 mg of sirolimus. The recommended dosage depends on the patient's body weight, clinical situation, and concomitant immunosuppressive therapy. It should be used orally only, and the quantity administered should be measured using a calibrated syringe. The medication must be kept out of reach of children and stored in a cool, dark place. If the solution turns cloudy, it should not be used. Individual syringes should be discarded after opening, and the contents of the bottle should be used within one month. If ingested in very high doses, the medication can be harmful to individuals with liver disease, pregnant women, and their fetuses.*
Figure (Sirolimus Oral Solution 2)
Figure-1 (Sirolimus Oral Solution 3)
Not available.*
Figure-2 (Sirolimus Oral Solution 4)
Figure-3 (Sirolimus Oral Solution 5)
Figure-4 (Sirolimus Oral Solution 6)
Figure-5 (Sirolimus Oral Solution 7)
Figure-6 (Sirolimus Oral Solution 8)
Figure-7 (Sirolimus Oral Solution 9)
This text is a description of Figure 7 showing how a syringe is being emptied into a glass.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
